Eli Lilly and Novo advance amylin-based therapies to complement GLP-1 obesity drugs
Eli Lilly and Novo are testing amylin-targeting drugs, both alone and in combination with existing GLP-1 treatments, aiming to improve weight-loss outcomes for patients with obesity and type 2 diabetes.
Eli Lilly reported that its experimental amylin analogue eloralintide, when added to tirzepatide, produced an average 23.3% body-weight reduction after 48 weeks in a Phase 2 study of patients with obesity and type 2 diabetes, compared with 14.8% for tirzepatide alone. The trial involved a high-dose combination regimen and assumed continuous treatment throughout the study period.
"These are encouraging results," said Benjamin Bikman, a professor at Brigham Young University who studies metabolic health.
Lilly plans to develop eloralintide as both a standalone therapy and as part of a combination product. Analysts project potential annual sales of $23.2 billion by 2035, with a standalone launch targeted for 2029 and a combination product in 2030. Ken Custer, president of Lilly Cardiometabolic Health, noted that some patients may not achieve sufficient results with tirzepatide alone or with eloralintide alone, suggesting a role for the combined approach.
The Phase 2 data came from a relatively small sample, and a higher discontinuation rate due to side effects was observed for the combination (10.8%–27%) versus tirzepatide alone (2.9%). Bikman emphasized that tolerability will be a key focus in upcoming Phase 3 trials.
Novo Nordisk is pursuing a similar strategy with its amylin analogue cagrilintide, which has shown weight-loss benefits as a monotherapy and greater loss when paired with semaglutide in the CagriSema regimen. Novo expects to launch CagriSema early next year, followed by standalone cagrilintide and a higher-dose version in 2028. The company also disclosed early Phase 2 results for amycretin (zenagamtide), a molecule that targets both GLP-1 and amylin receptors, being tested as a weekly injection and a daily oral tablet.
Researchers highlighted that amylin signals fullness and slows gastric emptying through a pathway distinct from GLP-1, offering a complementary mechanism. Novo’s chief scientific officer, Martin Holst Lange, said functional MRI studies indicated the CagriSema combination reduced neural responses to high-calorie foods, which the company linked to improved quality of life.
The development of multi-hormone regimens reflects a broader trend in obesity pharmacotherapy, with other candidates such as tirzepatide (GLP-1 + GIP) and Lilly’s retatrutide (GLP-1 + GIP + glucagon) also advancing. While early results are promising, the efficacy and safety of amylin-based combinations must be confirmed in larger Phase 3 trials and regulatory reviews before they can be widely prescribed.